{"name":"Azafaros A.G.","slug":"azafaros-a-g","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AZ-3102 (Dose 1)","genericName":"AZ-3102 (Dose 1)","slug":"az-3102-dose-1","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]}],"pipeline":[{"name":"AZ-3102 (Dose 1)","genericName":"AZ-3102 (Dose 1)","slug":"az-3102-dose-1","phase":"phase_3","mechanism":"AZ-3102 is a selective inhibitor of the retinoic acid receptor-related orphan receptor gamma t (RORγt) pathway.","indications":["Moderate to severe plaque psoriasis","Moderate to severe atopic dermatitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2023-09-19","type":"regulatory","source":"PR Newswire","summary":"Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos He","headline":"Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaro","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}